Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors

Summary

The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of PLX7486.

Timeline

Start

2013-08

Primary completion

2018-01-24

Completion

2018-01-24

Outcome

Outcome not reported

Stopped: “Discontinued”

Drugs

Indications